Univariate analysis at diagnosis for time to progression to multiple myeloma in patients with solitary plasmacytoma of bone
Parameter . | N . | Hazard ratio . | Confidence interval . | P . |
|---|---|---|---|---|
| Age | 116 | 1.02 | 1.00-1.04 | .078 |
| Male sex | 116 | 0.62 | 0.33-1.18 | .144 |
| Hemoglobin | 116 | 0.93 | 0.80-1.10 | .431 |
| Serum M spike | ||||
| Positive | 116 | 1.50 | 0.77-2.92 | .235 |
| Size | 116 | 1.17 | 0.84-1.62 | .360 |
| Urine M spike | ||||
| Positive | 105 | 2.55 | 1.33-4.89 | .005 |
| Size | 105 | 0.70 | 0.31-1.62 | .409 |
| Free light chain assay | ||||
| Ratio less than 0.26 or more than 1.65 | 116 | 1.89 | 1.03-3.45 | .039 |
| Ratio less than 0.25 or more than 4.0 | 116 | 2.14 | 1.17-3.95 | .014 |
| Elevated light chain | 107 | 1.68 | 0.89-3.16 | .107 |
| Reduced uninvolved Igs | 60 | 0.80 | 0.41-1.57 | .513 |
| Type of treatment | 116 | 1.67 | 0.91-3.05 | .095 |
| Site of plasmacytoma | 115 | 1.37 | 0.33-5.68 | .662 |
Parameter . | N . | Hazard ratio . | Confidence interval . | P . |
|---|---|---|---|---|
| Age | 116 | 1.02 | 1.00-1.04 | .078 |
| Male sex | 116 | 0.62 | 0.33-1.18 | .144 |
| Hemoglobin | 116 | 0.93 | 0.80-1.10 | .431 |
| Serum M spike | ||||
| Positive | 116 | 1.50 | 0.77-2.92 | .235 |
| Size | 116 | 1.17 | 0.84-1.62 | .360 |
| Urine M spike | ||||
| Positive | 105 | 2.55 | 1.33-4.89 | .005 |
| Size | 105 | 0.70 | 0.31-1.62 | .409 |
| Free light chain assay | ||||
| Ratio less than 0.26 or more than 1.65 | 116 | 1.89 | 1.03-3.45 | .039 |
| Ratio less than 0.25 or more than 4.0 | 116 | 2.14 | 1.17-3.95 | .014 |
| Elevated light chain | 107 | 1.68 | 0.89-3.16 | .107 |
| Reduced uninvolved Igs | 60 | 0.80 | 0.41-1.57 | .513 |
| Type of treatment | 116 | 1.67 | 0.91-3.05 | .095 |
| Site of plasmacytoma | 115 | 1.37 | 0.33-5.68 | .662 |